Brazilian Journal of Anesthesiology
https://bjan-sba.org/article/doi/10.1016/j.bjane.2014.02.017
Brazilian Journal of Anesthesiology
Scientific Article

Influence of preoperative propranolol on cardiac index during the anhepatic phase of liver transplantation

Influência do propranolol pré-operatório no índice cardíaco durante a fase anepática do transplante hepático

Emerson Seiberlich; Marcelo D. Sanches; Bruno S. Morais; Jader F. Maciel

http://dx.doi.org/10.1016/j.bjane.2014.02.017 Braz J Anesthesiol, vol.65, n3, p.170-176, 2015
PDF English
PDF Português
Downloads: 0
Views: 606

Abstract

INTRODUCTION: Liver transplantation is the best therapeutic option for end-stage liver disease. Non-selective beta-blocker medications such as propranolol act directly on the cardiovascular system and are often used in the prevention of gastrointestinal bleeding resulting from HP. The effects of propranolol on cardiovascular system of cirrhotic patients during liver transplantation are not known. OBJECTIVE: Evaluate the influence of propranolol used preoperatively on cardiac index during the anhepatic phase of liver transplantation. METHOD: 101 adult patients (73 male [72.2%]) who underwent cadaveric donor orthotopic liver transplantation by piggyback technique with preservation of the retrohepatic inferior vena cava performed at Hospital das Clinicas, Federal University of Minas Gerais were evaluated. There was no difference in severity between groups by the MELD system, p = 0.70. The preoperative use of propranolol and the cardiac index outcome were compared during the anhepatic phase of liver transplantation in 5 groups (I: increased cardiac index, II: cardiac index reduction lower than 16%, III: cardiac index reduction equal to or greater than 16% and less than 31%, IV: cardiac index reduction equal to or greater than 31% and less than 46%, V: cardiac index reduction equal to or greater than 46%). RESULTS: Patients in group I (46.4%) who received propranolol preoperatively were statistically similar to groups II (60%), III (72.7%), IV (50%) and V (30.8%), p = 0.57. CONCLUSION: The use of propranolol before transplantation as prophylaxis for gastrointestinal bleeding may be considered safe, as it was not associated with worsening of cardiac index in anhepatic phase of liver transplantation.

Keywords

Liver transplant, Cardiac output, Beta-adrenergic antagonist, Propranolol

Resumo

INTRODUÇÃO: O transplante hepático (TH) é a melhor opção terapêutica para doença hepática em estágio terminal (DHET). As medicações betabloqueadoras não seletivas, como o propranolol, atuam diretamente no sistema cardiovascular (SCV) e são frequentemente usadas na prevenção de hemorragia digestiva decorrente da HP. Os efeitos do propranolol no SCV de cirróticos durante o TH não são conhecidos. OBJETIVO: Avaliar a influência do uso pré-operatório do propranolol no índice cardíaco (IC) durante a fase anepática do TH. MÉTODO: Avaliaram-se 101 pacientes adultos (73 homens, 72,2%) submetidos a transplante ortotópico de fígado doador cadáver, pela técnica de piggyback com preservação da veia cava inferior retro-hepática, feito no Hospital das Clínicas da Universidade Federal de Minas Gerais. Não houve diferença de gravidade pelo sistema MELD entre os grupos, p = 0,70. Foram comparados o uso pré-operatório de propranolol com o desfecho do IC durante a fase anepática do TH em cinco grupos (I: aumento do IC; II: redução do IC inferior a 16%; III: redução do IC igual a ou maior do que 16% e menor do que 31%; IV: redução do IC igual a ou maior do que 31% e menor do que 46%;V: redução do IC igual a ou maior do que 46%). RESULTADOS: Pacientes que fizeram uso pré-operatório de propranolol no grupo I (46,4%) foram estatisticamente semelhantes aos dos grupos II (60%), III (72,7%), IV (50%) e V (30,8%), p = 0,57. CONCLUSÃO: O propranolol no pré-transplante, como profilaxia para hemorragia digestiva, pode ser considerado seguro, pois não se associou à pioria do IC na fase anepática do TH.

Palavras-chave

Transplante de fígado, Débito cardíaco, Antagonista adrenérgico beta, Propranolol

References

Starzl TE, Marchioro TL, Vonkaulla KN. Homotrans- plantation of the liver in humans. Surg Gynecol Obstet.. ;117:676-659.

Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplan- tation for hepatocellular carcinoma. Aliment Pharmacol Ther.. ;37:411-419.

Garcia-Tsao G, Sanyal AJ, Grace NDC. Preven- tion and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology.. ;46:922-938.

De Franchis R, Faculty BV. Revising consensus in portal hyper- tension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol.. ;53:762-768.

La Mura V, Abraldes JG, Raffa S. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. J Hepatol.. ;51:279-287.

Schepis F, Vukotic R, Berzigotti A. Hemodynamic response to propranolol in patients with recurrent HCV-related cirrhosis after liver transplantation: a case-control study. Liver Transpl.. ;19:450-456.

Ozier Y, Klinck JR. Anesthetic management of hepatic transplantation. Curr Opin Anaesthesiol.. ;21:391-400.

Black JW, Crowther AF, Shanks RG. A new adrenergic betarecptor antagonist. Lancet.. ;1:1081-1080.

Chrysant SG, Chrysant GS. Current status of β-blockers for the treatment of hypertension: an update. Drugs Today (Barc).. ;48:366-353.

Chen Yl, Ghali P. Prevention and management of gastro- esophageal varices in cirrhosis. lnt J Hepatol.. ;2012:150-750.

Lee RF, Glenn TK, Lee SS. Cardiac dysfunction in cirrhosis. Best Pract Res Clin Gastroenterol.. ;21:125-140.

Wong F, Girgrah N, Graba J. The cardiac response to exercise in cirrhosis. Gut.. ;49:268-275.

Figueras J, Llado L, Ramos E. Temporary portocaval shunt during liver transplantation with vena cava preserva- tion. Results of a prospective randomized study. Liver Transpl.. ;7:911-904.

Tzakis AG, Reyes J, Nour B. Temporary end to side por- tacaval shunt in orthotopic hepatic transplantation in humans. Surg Gynecol Obstet.. ;176:182-180.

Margarit C, de Cenarruzabeitia lL, Lázaro JL. Portacaval shunt and inferior vena cava preservation in orthotopic liver transplantation. Transplant Proc.. ;37:3898-3896.

Muscari F, Suc B, Aguirre J. Orthotopic liver transplan- tation with vena cava preservation in cirrhotic patients: is systematic temporary portacaval anastomosis a justified pro- cedure?. Transplant Proc.. ;37:2159-2162.

Raval Z, Harinstein ME, Skaro Al. Cardiovascular risk assessment of the liver transplant candidate. J Am Coll Cardiol.. ;58:223-231.

Yang YY, Lin HC. The heart: pathophysiology and clinical implications of cirrhotic cardiomyopathy. J Chin Med Assoc.. ;75:623-619.

Ma Z, Miyamoto A, Lee SS. Role of altered beta-adrenoceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. Gastroenterology.. ;110:1191-1198.

Vilas-Boas WW, Ribeiro-Oliveira A, Ribeiro Rda C. Effect of propranolol on the splanchnic and peripheral renin angiotensin system in cirrhotic patients. World J Gastroenterol.. ;14:6830-6824.

Arranz J, Soriano A, Garcia l. Effect of proinflammatory cytokines (lL-6, TNF-alpha, lL-1beta) on hemodynamic perfor- mance during orthotopic liver transplantation. Transplant Proc.. ;35:1887-1884.

Hartemink KJ, Groeneveld AB. Vasopressors and inotropes in the treatment of human septic shock: effect on innate immunity?. lnflammation.. ;35:213-206.

Zanotti-Cavazzoni SL, Hollenberg SM. Cardiac dysfunction in severe sepsis and septic shock. Curr Opin Crit Care.. ;15:392-397.

5dd2a7b80e8825c56dc63493 rba Articles
Links & Downloads
2352-2291 (Electronic) 0104-0014 (Printed)
Braz J Anesthesiol ©2024 All rights reserved.

Braz J Anesthesiol

Share this page
Page Sections